CAV1 is a scaffolding protein encoded that is a primary component of caveolae plasma membranes in most cell types. CAV1 plays an important role in cell metabolism and is involved in autophagy, fatty acid metabolism, glutaminolysis, glycolysis and mitochondrial bioenergetics. Mutations in this gene have been associated with Berardinelli-Seip congenital lipodystrophy. In cancer, CAV1 can be a driver of tumorigenesis and also a suppressor in different contexts. For example, it appears to have an oncogenic role and may be an effective target of therapy in triple negative breast cancer with aberrant TP53 expression. Conversely, higher expression of CAV1 in some liver cancer patients is associated with improved survival, and loss of CAV1 alongside APC knockout has been shown to increase colorectal tumorigenesis. In immunohistochemistry of normal tissue, it has membranous positivity in endothelial cells, adipocytes, as well as pneumocytes and basal cells of squamous epithelia in various tissues throughout the body. References: The UniProt Consortium. Nucleic Acids Res. 47: D506-515 (2019); Nucleic Acids Res. 2016 Jan 4;44(D1):D733-45, PMID:26553804; Onco Targets Ther. 2019; 12: 1539–1552, PMID: 30881011; Mol Cancer 15, 71 (2016), DOI:10.1186/s12943-016-0558-7; Journal of Clinical Oncology 2015 33:28_suppl, 134-134, DOI: 10.1200/jco.2015.33.28_suppl.134;